Szopa Aleksandra, Poleszak Ewa, Wyska Elżbieta, Serefko Anna, Wośko Sylwia, Wlaź Aleksandra, Pieróg Mateusz, Wróbel Andrzej, Wlaź Piotr
Department of Applied Pharmacy, Medical University of Lublin, Chodźki 1, PL 20-093, Lublin, Poland.
Department of Pharmacokinetics and Physical Pharmacy, Collegium Medicum, Jagiellonian University, Medyczna 9, PL 30-688, Kraków, Poland.
Naunyn Schmiedebergs Arch Pharmacol. 2016 Feb;389(2):211-21. doi: 10.1007/s00210-015-1189-z. Epub 2015 Nov 27.
Caffeine is the most widely used behaviorally active drug in the world which exerts its activity on central nervous system through adenosine receptors. Worrying data indicate that excessive caffeine intake applies to patients suffering from mental disorders, including depression. The main goal of the present study was to evaluate the influence of caffeine on animals' behavior in forced swim test (FST) as well as the effect of caffeine (5 mg/kg) on the activity of six typical antidepressants, such as imipramine (15 mg/kg), desipramine (10 mg/kg), fluoxetine (5 mg/kg), paroxetine (0.5 mg/kg), escitalopram (2 mg/kg), and reboxetine (2.5 mg/kg). Locomotor activity was estimated to verify and exclude false-positive/negative results. In order to assess the influence of caffeine on the levels of antidepressant drugs studied, their concentrations were determined in murine serum and brains using high-performance liquid chromatography. The results showed that caffeine at a dose of 10, 20, and 50 mg/kg exhibited antidepressant activity in the FST, and it was not related to changes in locomotor activity in the animals. Caffeine at a dose of 5 mg/kg potentiated the activity of all antidepressants, and the observed effects were not due to the increase in locomotor activity in the animals. The interactions between caffeine and desipramine, fluoxetine, escitalopram, and reboxetine were exclusively of pharmacodynamic character, because caffeine did not cause any changes in the concentrations of these drugs neither in blood serum nor in brain tissue. As a result of joint administration of caffeine and paroxetine, an increase in the antidepressant drug concentrations in serum was observed. No such change was noticed in the brain tissue. A decrease in the antidepressant drug concentrations in brain was observed in the case of imipramine administered together with caffeine. Therefore, it can be assumed that the interactions caffeine-paroxetine and caffeine-imipramine occur at least in part in the pharmacokinetic phase.
咖啡因是世界上使用最广泛的具有行为活性的药物,它通过腺苷受体对中枢神经系统发挥作用。令人担忧的数据表明,过量摄入咖啡因的情况在患有精神障碍(包括抑郁症)的患者中存在。本研究的主要目的是评估咖啡因对动物在强迫游泳试验(FST)中的行为的影响,以及咖啡因(5毫克/千克)对六种典型抗抑郁药活性的影响,这些抗抑郁药包括丙咪嗪(15毫克/千克)、地昔帕明(10毫克/千克)、氟西汀(5毫克/千克)、帕罗西汀(0.5毫克/千克)、艾司西酞普兰(2毫克/千克)和瑞波西汀(2.5毫克/千克)。通过评估自发活动来验证并排除假阳性/阴性结果。为了评估咖啡因对所研究的抗抑郁药水平的影响,使用高效液相色谱法测定了小鼠血清和大脑中这些药物的浓度。结果表明,剂量为10、20和50毫克/千克的咖啡因在FST中表现出抗抑郁活性,且这与动物自发活动的变化无关。剂量为5毫克/千克的咖啡因增强了所有抗抑郁药的活性,且观察到的效果并非由于动物自发活动的增加。咖啡因与地昔帕明、氟西汀、艾司西酞普兰和瑞波西汀之间的相互作用完全是药效学性质的,因为咖啡因在血清和脑组织中均未引起这些药物浓度的任何变化。咖啡因与帕罗西汀联合给药后,血清中抗抑郁药浓度升高。脑组织中未观察到此类变化。咖啡因与丙咪嗪联合给药时,脑组织中抗抑郁药浓度降低。因此,可以假定咖啡因 - 帕罗西汀和咖啡因 - 丙咪嗪之间的相互作用至少部分发生在药代动力学阶段。